The novel gluconeogenesis inhibitor FR225654 that originates from Phoma sp. no. 00144. II. Biological activities

J Antibiot (Tokyo). 2005 Jul;58(7):452-5. doi: 10.1038/ja.2005.59.

Abstract

The novel gluconeogenesis inhibitor FR225654, isolated from the culture broth of Phoma sp. No. 00144, has an unique structure that consists of a highly oxygenated trans-decalin ring and a beta-keto-enol, with a characteristic side chain. This compound selectively inhibited gluconeogenesis of rat primary hepatocytes and had hypoglycemic effects in several in vivo mouse models.

MeSH terms

  • Administration, Oral
  • Animals
  • Blood Glucose / drug effects*
  • Cells, Cultured
  • Diabetes Mellitus, Experimental / drug therapy
  • Gluconeogenesis / drug effects*
  • Hepatocytes / drug effects*
  • Hepatocytes / metabolism
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / pharmacology*
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Naphthalenes / administration & dosage
  • Naphthalenes / pharmacology*
  • Naphthalenes / therapeutic use
  • Rats

Substances

  • Blood Glucose
  • FR225654
  • Hypoglycemic Agents
  • Naphthalenes